Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:14 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Augmenting Cerebral Blood Flow to Treat Established Multiple Sclerosis
NCT02466074 · The University of Texas Health Science Center, Houston · PHASE2 · terminated · last registry update 2023-04-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Inadequate recruitment; termination of funding” | – | Registry record, The University of Texas Health Science Center, Houston |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-03-01Also stopped (withdrawn): University of Alabama at Birmingham, [O-15]Water + Acetazolamide (NCT03806751)
- 2024-01-31Results posted on the registry: Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-31Also stopped (terminated): Vanderbilt University Medical Center, Opioid Analgesic + Opioid-Free Postoperative Pain Regimen (NCT04990804)
- 2024-01-03Results posted on the registry: CrystalGenomics, Inc., CG100649 + Ketoconazole (NCT01154764)
- 2023-12-12Phase 3 first posted: Johannes Grand, Acetazolamide + Metolazone 2.5 MG (NCT06166654)
- 2023-11-24Phase 3 first posted: Incannex Healthcare Ltd, IHL-42X Low Dose + IHL-42X High Dose (NCT06146101)
- 2023-07-27Results posted on the registry: University of Wisconsin, Madison, Acetazolamide (NCT03377049)
- 2023-07-11Phase 3 first posted: Tehran University of Medical Sciences, a drug against CA1 (NCT05940220)
- 2023-02-15Results posted on the registry: CrystalGenomics, Inc., CG100649 + Celecoxib (NCT01765296)
- 2023-02-09Results posted on the registry: CrystalGenomics, Inc., CG100649 + Celecoxib (NCT01341405)
- 2023-02-01Phase 3 first posted: Beijing Tiantan Hospital, Acetazolamide-based medical therapy (NCT05707442)
- 2023-01-12Results posted on the registry: University of Vermont Medical Center, a drug against CA1 (NCT03846024)
- 2023-01-12Also stopped (terminated): University of Vermont Medical Center, a drug against CA1 (NCT03846024)
- 2022-12-12Also stopped (withdrawn): West Virginia University, Sufentanil (NCT04464512)
- 2022-11-03Phase 3 first posted: Arthritis Innovation Corporation, F14 + 0.25 % Bupivacaine HCl (NCT05603832)
- 2022-06-16Results posted on the registry: Jaeb Center for Health Research, Acetazolamide (NCT03501966)
- 2022-06-16Also stopped (terminated): Jaeb Center for Health Research, Acetazolamide (NCT03501966)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision